文献速递哮喘

改善学龄前喘息管理与结局:前瞻性多中心队列研究方案

Improving the management and outcomes of preschool wheeze: protocol of a prospective multicentre cohort study
RSS 订阅 · BMJ Open Respiratory Research

本研究为多中心前瞻性队列研究,计划招募102名0.5–6岁疑似哮喘的学龄前儿童,评估在常规临床评估中加入WheezeScan(一种基于人工智能客观定义喘息及其支气管舒张剂反应的数字设备)能否提高哮喘确诊率。主要假设是使用WheezeScan与更多确定性哮喘诊断相关,次要假设是改善患者报告结局且不增加医疗费用。

要点

  • 学龄前喘息与哮喘患病率高,但家长与医生对喘息的判断分歧超过50%。
  • WheezeScan利用人工智能客观识别喘息及支气管舒张剂反应。
  • 研究评估WheezeScan对哮喘确诊率、患者报告结局和医疗费用的影响。

核心结论

  • 研究旨在确定在学龄前疑似哮喘儿童中,常规评估加用WheezeScan是否较不加用提高确定性哮喘诊断比例。

研究设计与样本

  • 多中心前瞻性队列研究,计划招募102名0.5–6岁疑似哮喘的学龄前儿童。
  • 家长/照护者使用WheezeScan每天两次并在怀疑喘息时使用,持续6周;若检测到喘息则给予吸入短效β2受体激动剂并判断喘息是否缓解。

关键数值与推荐

  • 主要终点为基于治疗临床医生使用WheezeScan数据评估的确定性哮喘诊断比例,与基线比较。
  • 次要结局为反映普适健康相关生活质量和咳嗽特异性(如存在慢性咳嗽)结局的患者报告结局及医疗费用。

临床怎么用

  • WheezeScan为客观定义喘息及其可逆性提供工具,可能辅助学龄前哮喘的早期诊断和管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Introduction Preschool wheeze and asthma are associated with substantial morbidity and impaired future lung function. Yet, wheeze is unreliably reported with high disagreement (>50%) between parental and physician observations. Objectively defining wheeze and its reversibility could enable an earlier asthma diagnosis and improve preschool wheeze management. Our primary aim is to determine in preschool children (aged 0.5–6 years) suspected of asthma whether adding WheezeScan to routine clinical assessment (vs assessment without WheezeScan) improves the diagnosis of asthma. Our primary hypothesis is that using WheezeScan in preschool children suspected of asthma is associated with increased definitive asthma diagnoses in this age group. Our secondary aims are to (a) examine the effect of using WheezeScan on patient-reported outcomes (PROs) and (b) healthcare costs. Our secondary hypothesis is that using WheezeScan in preschool children suspected of asthma is associated with improved quality of life without incurring additional healthcare costs. Methods and analysis Our multicentre prospective cohort study involves recruiting 102 preschool children suspected of asthma. WheezeScan, a user-friendly digital device, incorporates artificial intelligence to objectively define wheeze and its response to bronchodilators. Over 6 weeks, parents/caregivers use the WheezeScan two times per day and whenever wheezing is suspected. If wheeze is detected, an inhaled short-acting β 2 -agonist is administered and WheezeScan determines if wheeze resolves thereafter. Our primary endpoint is the proportion of children with a definitive asthma diagnosis, compared with baseline, based on the treating clinician’s assessment using WheezeScan data. Our secondary outcomes are PROs, reflecting generic health-related quality-of-life and cough-specific (if chronic cough present) outcomes and health costs. Ethics and dissemination The Children’s Health Queensland Human Research Ethics Committee (HREC/23/QCHQ/100691) and the Queensland University of Technology Office of Research Ethics and Integrity approved the study. We will publish and share results with the academic and healthcare communities and relevant patient organisations. Trial registration number Australian New Zealand Clinical Trials Registry ACTRN12623000904673.

来源:BMJ Open Respiratory Research,查看原文。版权归原作者所有。

引用

  1. BMJ Open Respiratory Research:Improving the management and outcomes of preschool wheeze: protocol of a prospective multicentre cohort study

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。